Banks to Pitch Roughly €11 Billion Buyout Debt Deal for Grifols
Banks are getting ready to submit final offers to Brookfield Asset Management for a debt package of about €11 billion ($11.6 ...
Grifols holder Mason Capital against potential Brookfield deal
Mason Capital opposes Grifols sale to Brookfield Asset Management, raising concerns about the potential acquisition in the ...
Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors
Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of ...
Grifols on track to meet 2024 targets as core earnings rise
MADRID (Reuters) -Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net ...
EQS-News: Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million
EQS-News: Biotest AG / Key word (s): 9 Month figures Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million 14.11.2024 / 10:14 CET/CEST The issuer is solely responsible for ...
Business Insider6h
EQS-Adhoc: Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged
This includes revenues from technology disclosure and from development services for Grifols, S.A. Previously, an increase in the high single-digit percentage range had been expected. The return on ...
Grifols Shares Rise After 3Q Sales Beat Views
Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division. Shares traded 4.7% higher ...
PharmiWeb6h
Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged
Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged14-Nov-2024 / 08:56 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No ...
The Lancet6h
Amyloid-lowering treatment in Alzheimer's disease
We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...